HEALTH OF WOMAN. 2016.2(108):49–52 
 

Bioregulatory opportunities of Viburkol and Limphomiozot medicines in obstetries and gynecology 
 

Ostapenko O.

«Institute of family planning» LLC, Kyiv 
 

Modern obstetrics and gynecology use a wide range of medicines (drugs) when accompanied by pregnancy and childbirth (miscarriage, discoordination labor, labor pain relief), diseases of the female reproductive system (inflammation, dishormonal disorders, etc..). Among the traditional drugs most widely used antibiotics, NSAIDs, analgesics, antispasmodics, hormones. These drugs, along with the achievement of rapid and pronounced therapeutic effects cause different side effects, and have a number of contra-indications (diseases of the liver, the pancreas, the risk of thrombosis, the development of immunodeficiency, etc.) [12]. In this regard, special attention and care requires the use of drugs in pregnant women and nursing mothers. Also relevant is the increase of efficiency of treatment of many gynecological diseases. All these and many other factors encourage to search for new – more effective and safer treatment approaches and drugs, including pathogenesis [12, 22]. The review presents brief characteristics and clinical researches on the use and integrated bioregulatory approach through the use of complex combination bioregulatory medicines (CBM) Viburkol, Limphomiozot, Limphomiozot N in obstetrics and in various diseases and disorders of the female reproductive system [1–3]. The research results show that the inclusion of one or more of the CBM in the traditional treatment help reduce the duration of therapy, a decrease in some side effects, and in some cases rejection of it. In addition, they do not burden for opportunistic diseases, tolerated well and have a favorable safety profile, can be used during pregnancy and lactation [4–22].

Key words: Viburkol, Limphomiozot, Limphomiozot N, bioregulatory approach, combination bioregulatory medicines, obstetrics, gynecology, diseases of the female reproductive system.

REFERENCES

1. Heine Hartmut. 2004. The value of antihomotoxic therapy in regulatory medicine. Biological Medicine 2: 4-9.

2. Klimenko VG. 2013. The main provisions of pathogenic bio-regulatory approach in general therapeutic practice. Biological Therapy 1: 8-11.

3. Van Brandt B, Heine H., 2006. Regulatory blockade: definition, meaning and treatment. Biological medicine: 4-5.

4. Rekveg GG. 1997. Homeopathic antigomotoxicology. Homeopathic medicine. Smolensk: 591.

5. Shamugia BK, Timoshkov MV. 2013. Bio-regulatory approach to the treatment of pain. Therapia. 2 (77): 75-78.

6. Possible applications of Viburkol in the pediatric, obstetric and gynecological practice. News of medicine and pharmacy. 2013. 5 (449): 10-11.

7. Kramarskiy VA Dudakova VN. 2008. Antihomotoxic therapy in the prevention of discoordination labor. Biological Medicine 2: 23-24.

8. Tyraspolskiy IW, Kashirina TN, Busorgina OV, Kuzmin VN, Sovdagarova UE. 1998. Efficacy of homeopathic candles Viburkol under anesthesia delivery. Biological Medicine 1: 35-38.

9. Manukhin IB, Kashirina TN, Tyraspolskiy IW, Busorgina OV, Hareb LV. 1998. The use of the homeopathic method in obstetrics. Guidelines number 137/98 Ministry of Health of Russia. M: 18.

10. Tyraspolskiy IW Kashirina TN, Busorgina OV, Sovdagarova UE. 1999. The methodology and experience of conducting therapy threatening miscarriage in the first trimester of pregnancy is complex homeopathic preparations. Biological Medicine 1: 40-44.

11. Leush SS, Oleinik UV, Olejnik EA. 2010. Optimization of treatment of inflammatory diseases of the genital organs and prevention of adhesions in women of reproductive age. Guidelines Ministry of Health of Ukraine. K: 32.

12. Leush SS, Oleinik UV. 2006. Antihomotoxic treatment of gynecological diseases. Guidelines Ministry of Health of Ukraine. K: 30.

13. Chursina TY, Mikhalev KA. 2006. Allopathic and antihomotoxic therapy of acute inflammation: alternative or complementary way? Biological Therapy 1: 17-21.

14. Limfomiozot – effective lymphatic drainage and anti-complex biological product. Biological therapy. 2013. 1: 42-44.

15. Antihomotoxic therapy in the treatment of chronic inflammation in gynecology: efficacy and safety. The art of therapy. 2008, 3 (49): 58-60.

16. Lakhno IV. 2007. Antihomotoxic drugs and reproductive function of women. Medical aspects of women's health 3 (6): 31-34.

17. Podolskyy VV, Dronova VL, Podolskyy VlV. 2002. Treatment of chronic inflammatory diseases of the genital organs of women of childbearing age using Gynacoheel and Lymphomyosot drugs. Biological Therapy 1: 3-7.

18. Parkhomenko AP. 2003. Rehabilitation of the female reproductive function after myocardial salpingoophoritis. Author. diss. cand. med. Sciences (Ministry of health Ukraine).

19. Podolskyy VV Dronova VL, Latysheva ZM, Teterin VV, Gerevich GJ, Teslyuk RS, Fedunov US. 2006. Infectious and inflammatory processes of female genital in pregnant women and their treatment antihomotoxic medications. Guidelines Ministry of Health of Ukraine. K: 26.

20. Tatarchuk TF, Zakharenko NF. 2005. Optimization of treatment of chronic endocervicoses in women infected with human papillomavirus. Biological Therapy 4: 14-18.

21. Tatarchuk TF, Lysianaia TA, Zadorozhnaya TD, Burlaka OV, Korena KO. 2005 Modern features of the treatment of endometrial polyposis. Byolohycheskaya therapy 4: 34-36.